Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altimmune, Inc.ALT · Entity 5349 | Chief Medical Officer | July 31, 2025 | August 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altimmune, Inc.
Report date July 31, 2025 · Filed August 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 16,087 |
Reported balance
After 2025-07-31 transaction · row 1
1 source rowRow 1 · 2025-07-31 · Grant · Acquired 2,018 · Balance 16,087 F1: These shares were purchased due to participation of the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2025 through July 31, 2025. F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock. |
| Common Stock, par value $0.0001SEC Table I · non-derivative | IndirectBy Matthew Scott Harris Trust | 67,787 |
Reported balance
Holding disclosure · report date 2025-07-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 67,787 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were purchased due to participation of the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2025 through July 31, 2025.
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2025 Filed Aug 4, 2025 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 2,018 | $3.14 | $6,336.52 |
DisclosureSEC source: 0001104659-25-073627 · tm2522384-2_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,087 F1 · kind: These shares were purchased due to participation of the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2025 through July 31, 2025. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | GiftCommon Stock, par value $0.0001 | 67,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-022550 · tm258873-1_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,069 F1 · ownership.direct: On March 7, 2025, the reporting person transferred 67,787 shares of common stock to the Matthew Scott Harris Trust for no consideration. The reporting person is trustee of the trust, and the reporting person and members of his immediate family are the sole beneficiaries of the trust. The reporting person remains the beneficial owner of the securities held by the trust. Read SEC document |
| February 02, 2025 Filed Feb 4, 2025 01:48 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008772 · tm255357-3_4seq1.xml · derivative · entry 10 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,775 Underlying: Common Stock, par value $0.0001 · 7,775 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F7 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F7 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2025 Filed Feb 4, 2025 01:48 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,708 | $6.64 | $17,981.12 |
DisclosureSEC source: 0001104659-25-008772 · tm255357-3_4seq1.xml · nonDerivative · entry 7 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,856 F1 · kind: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 02, 2025 Filed Feb 4, 2025 01:48 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008772 · tm255357-3_4seq1.xml · nonDerivative · entry 6 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 01:48 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008772 · tm255357-3_4seq1.xml · derivative · entry 9 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 · 6,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F6 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F6 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 01:48 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,109 | $6.64 | $14,003.76 |
DisclosureSEC source: 0001104659-25-008772 · tm255357-3_4seq1.xml · nonDerivative · entry 5 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,789 F1 · kind: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 01:48 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008772 · tm255357-3_4seq1.xml · nonDerivative · entry 4 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:48 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 1,905 | $5.18 | $9,867.90 |
DisclosureSEC source: 0001104659-25-008772 · tm255357-3_4seq1.xml · nonDerivative · entry 3 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,732 F3 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2024 through January 31, 2025. F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2024. Read SEC document |
| January 30, 2025 Filed Feb 4, 2025 01:48 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 9,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008772 · tm255357-3_4seq1.xml · derivative · entry 8 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,550 Underlying: Common Stock, par value $0.0001 · 9,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 30, 2025 Filed Feb 4, 2025 01:48 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,173 | $7.00 | $22,211.00 |
DisclosureSEC source: 0001104659-25-008772 · tm255357-3_4seq1.xml · nonDerivative · entry 2 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,827 F1 · kind: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 30, 2025 Filed Feb 4, 2025 01:48 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 9,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008772 · tm255357-3_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 02:05 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 63,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006841 · tm254755-2_4seq1.xml · derivative · entry 5 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,400 Underlying: Common Stock, par value $0.0001 · 63,400 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 02:05 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 183,600 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006841 · tm254755-2_4seq1.xml · derivative · entry 4 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,600 Underlying: Common Stock, par value $0.0001 · 183,600 shares Expires 2035-01-27 F4 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and released on January 27, 2026 and the remaining 75% of the shares underlying the option become vested and released in substantially equal monthly installments over the 36 months following January 27, 2026, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| January 25, 2025 Filed Jan 29, 2025 02:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 14,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006841 · tm254755-2_4seq1.xml · derivative · entry 3 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,800 Underlying: Common Stock, par value $0.0001 · 14,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 25, 2025 Filed Jan 29, 2025 02:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 4,994 | $6.98 | $34,858.12 |
DisclosureSEC source: 0001104659-25-006841 · tm254755-2_4seq1.xml · nonDerivative · entry 2 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,725 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 25, 2025 Filed Jan 29, 2025 02:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 14,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006841 · tm254755-2_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| July 31, 2024 Filed Aug 1, 2024 21:40 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 1,486 | $5.41 | $8,039.26 |
DisclosureSEC source: 0001104659-24-084991 · tm2420669-1_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,119 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2024 through July 31, 2024. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 31, 2024. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010779 · tm245213-2_4seq1.xml · derivative · entry 6 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,550 Underlying: Common Stock, par value $0.0001 · 7,775 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F4 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F4 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,332 | $9.32 | $21,734.24 |
DisclosureSEC source: 0001104659-24-010779 · tm245213-2_4seq1.xml · nonDerivative · entry 4 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,633 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010779 · tm245213-2_4seq1.xml · nonDerivative · entry 3 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010779 · tm245213-2_4seq1.xml · derivative · entry 5 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,166 Underlying: Common Stock, par value $0.0001 · 6,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 1,801 | $9.88 | $17,793.88 |
DisclosureSEC source: 0001104659-24-010779 · tm245213-2_4seq1.xml · nonDerivative · entry 2 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,190 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010779 · tm245213-2_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 3,257 | $2.69 | $8,761.33 |
DisclosureSEC source: 0001104659-24-009540 · tm244961-3_4seq1.xml · nonDerivative · entry 3 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,825 F3 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2023 through January 31, 2024. F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2023. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 9,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-009540 · tm244961-3_4seq1.xml · derivative · entry 4 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,825 Underlying: Common Stock, par value $0.0001 · 9,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,709 | $9.80 | $26,548.20 |
DisclosureSEC source: 0001104659-24-009540 · tm244961-3_4seq1.xml · nonDerivative · entry 2 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,568 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 9,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-009540 · tm244961-3_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 23:31 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 58,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-007861 · tm244341-3_4seq1.xml · derivative · entry 2 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,400 Underlying: Common Stock, par value $0.0001 · 58,400 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 23:31 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 163,200 | $0.00 Strike: $9.28 | $0.00 |
DisclosureSEC source: 0001104659-24-007861 · tm244341-3_4seq1.xml · derivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,200 Underlying: Common Stock, par value $0.0001 · 163,200 shares Expires 2034-01-25 F1 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on January 25, 2025 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 25, 2025, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 21:49 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 691 | $2.81 | $1,941.71 |
DisclosureSEC source: 0001104659-23-086905 · tm2322669-3_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,002 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2023 through July 31, 2023. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 31, 2023. Read SEC document |
| March 23, 2023 Filed Mar 24, 2023 00:28 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 10,000 | $4.22 | $42,200.00 |
DisclosureSEC source: 0001104659-23-036172 · tm2310423-1_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,311 Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 21:31 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-011211 · tm235551-2_4seq1.xml · derivative · entry 3 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,325 Underlying: Common Stock, par value $0.0001 · 7,775 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 21:31 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,364 | $15.04 | $35,554.56 |
DisclosureSEC source: 0001104659-23-011211 · tm235551-2_4seq1.xml · nonDerivative · entry 2 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,311 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 21:31 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-011211 · tm235551-2_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-009974 · tm235311-3_4seq1.xml · derivative · entry 4 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,332 Underlying: Common Stock, par value $0.0001 · 6,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,183 | $13.78 | $30,081.74 |
DisclosureSEC source: 0001104659-23-009974 · tm235311-3_4seq1.xml · nonDerivative · entry 3 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,900 F4 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-009974 · tm235311-3_4seq1.xml · nonDerivative · entry 2 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 22:10 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 1,296 | $10.21 | $13,230.22 |
DisclosureSEC source: 0001104659-23-009974 · tm235311-3_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,917 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2022 through January 31, 2023. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2022. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 22:30 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 37,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-009352 · tm235142-1_4seq1.xml · derivative · entry 2 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,100 Underlying: Common Stock, par value $0.0001 · 37,100 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 22:30 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 105,000 | $0.00 Strike: $12.88 | $0.00 |
DisclosureSEC source: 0001104659-23-009352 · tm235142-1_4seq1.xml · derivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock, par value $0.0001 · 105,000 shares Expires 2033-01-30 F1 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on January 30, 2024 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 30, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| July 31, 2022 Filed Aug 3, 2022 20:08 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 1,076 | $6.86 | $7,381.36 |
DisclosureSEC source: 0001104659-22-085624 · tm2222488-3_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,621 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2022 through July 31, 2022. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 30,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001104659-22-029462 · tm228203-1_4seq1.xml · derivative · entry 3 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,400 Underlying: Common Stock, par value $0.0001 · 30,000 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent of the shares underlying the option became vested and exercisable on January 2, 2021 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 2, 2021, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | SaleCommon Stock, par value $0.0001 | 30,000 | $7.52 | $225,600.00 |
DisclosureSEC source: 0001104659-22-029462 · tm228203-1_4seq1.xml · nonDerivative · entry 2 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,545 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.70, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 30,000 | $1.92 | $57,639.00 |
DisclosureSEC source: 0001104659-22-029462 · tm228203-1_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 00:56 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 31,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011519 · tm225504-3_4seq1.xml · derivative · entry 6 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,100 Underlying: Common Stock, par value $0.0001 · 31,100 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F7 · derivative.exercise_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F7 · derivative.expiration_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 00:56 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 91,600 | $0.00 Strike: $7.53 | $0.00 |
DisclosureSEC source: 0001104659-22-011519 · tm225504-3_4seq1.xml · derivative · entry 5 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,600 Underlying: Common Stock, par value $0.0001 · 91,600 shares Expires 2032-02-02 F6 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on February 2, 2023 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following February 2, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:56 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011519 · tm225504-3_4seq1.xml · derivative · entry 4 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,498 Underlying: Common Stock, par value $0.0001 · 6,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:56 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,183 | $7.98 | $17,420.34 |
DisclosureSEC source: 0001104659-22-011519 · tm225504-3_4seq1.xml · nonDerivative · entry 3 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,545 F4 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:56 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011519 · tm225504-3_4seq1.xml · nonDerivative · entry 2 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.